Please refer to Phase I studies for more clinical trial opportunities.

**Melanoma**

**Adjuvant Therapies**

<table>
<thead>
<tr>
<th>Stage 2b or 2c</th>
<th>Stage 2b, 2c or 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB# 19679</td>
<td>IRB#11848</td>
</tr>
<tr>
<td>Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study</td>
<td>Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence</td>
</tr>
</tbody>
</table>

**Observational**

| IRB#17104 DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study |

**Uveal Melanoma**

| IRB# 21536 A Phase 2 trial of AU-011 via suprachoroidal administration designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma |

**Stage 3 or 4 Resectable**

| IRB #15661 A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma |
| IRB #16883 A Phase III, Randomized Study of Nivolumab with Ipilimumab vs. Ipilimumab or Nivolumab Monotherapy Post-resection |

| Moderna A Phase II randomized study of adjuvant immunotherapy with Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma |

**CROSS-DISEASE TRIALS:**

- IRB# TBD EAY131 (MATCH)
- IRB# TBD S1609 (DART)

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

[05/27/2021]

http://www.ohsu.edu/research/rda/so/knight.php
Please refer to Phase I studies for more clinical trial opportunities.

**IRB 16198**
A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

**IRB 19667**
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib+ Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAF V600-Mutant Melanoma Brain Metastasis

**Melanoma**
Stage 3 or 4, Unresectable

**Non-Mutation Specific**

**IRB 19207**
A Phase 3 Randomized Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)

**IRB 19943**
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma

**IRB 19285**
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Melanoma + Non-melanoma skin cancer

IRB 22389:
A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab in Patients with Advanced Solid Tumors

IRB 22483:
A Randomized, Controlled Study to Assess the Efficacy of the Tryl Software Application vs. Standard Reminders on the Response and Adherence Rate of Melanoma Community Registry Members

http://www.ohsu.edu/research/rda/so/knight.php